Shares of BioArctic AB tumbled by 7% on Friday following news that the European Commission (EC) has requested further review of the company's Alzheimer's drug, lecanemab, by the Committee for Medicinal Products for Human Use (CHMP).

The European Commission said on Friday that it has launched infringement procedures against Bulgaria for failing to fully transpose seven EU directives related

The European Commission has published on the 29th January the “Competitiveness Compass for the EU”, setting out ambitious initiatives aimed

Akhtar Ahmed, senior secretary of the Election Commission (EC), said that the European Union (EU) has emphasized the need to restore voter confidence. On Thursday, ahead of a meeting with the Election Commission at Agargaon,

The European Commission (EC) has presented data regarding several criminal proceedings linked to the enforcement of EU law, with Bulgaria involved in seven of these cases. In the realm of crime prevention,

AMM Nasir Uddin on Tuesday said the European Union (EU) has put emphasis on reform and assured all sorts of assistance ahead of the next general election. “They (EU) are ready to provide all sorts of assistance.

Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its antibody-drug conjugate Dato-DXd marketed with AstraZeneca (NASDAQ:AZN) as a late-line option for certain cases of breast cancer.

On 15 January the European Commission (“EC”) took its latest (prudent) step towards an outbound investment screening regime, with the publication

Merck (MRK) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, recommended

Unife has warned that EU member states are at risk of losing funding for vital rail schemes promised in the EU's Recovery and Resilience Facility.

The European Union's upcoming Digital Fairness Act has the potential to end exploitative practices online and enhance consumer protection throughout the modern digital ecosystem, but civil society gro

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the region's drug regulator to reconsider a prior decision that endorsed the anti-amyloid therapy.